- Previous Close
5.89 - Open
6.00 - Bid 6.17 x 100
- Ask 6.26 x 100
- Day's Range
5.99 - 6.37 - 52 Week Range
5.01 - 12.75 - Volume
367,530 - Avg. Volume
498,407 - Market Cap (intraday)
424.691M - Beta (5Y Monthly) 2.26
- PE Ratio (TTM)
-- - EPS (TTM)
-2.24 - Earnings Date Oct 31, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
38.22
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
compasspathways.com186
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: CMPS
View More
Performance Overview: CMPS
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CMPS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CMPS
View MoreValuation Measures
Market Cap
402.81M
Enterprise Value
206.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.78
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.22%
Return on Equity (ttm)
-70.90%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-139.21M
Diluted EPS (ttm)
-2.24
Balance Sheet and Cash Flow
Total Cash (mrq)
228.63M
Total Debt/Equity (mrq)
14.42%
Levered Free Cash Flow (ttm)
-54.37M
Research Analysis: CMPS
View MoreCompany Insights: CMPS
CMPS does not have Company Insights